Immunome, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: James Boylan

Immunome, Inc.’s own tally for this item (“Elect Director: James Boylan”): 70,209,570 for, 22,171,996 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or …”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 42,977,375 for, 5,116,087 withheld, 79 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Philip Wagenheim

Immunome, Inc.’s own tally for this item (“Elect Director: Philip Wagenheim”): 92,162,632 for, 218,934 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or …”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 48,078,807 for, 14,733 withheld, 1 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Sandra Swain, M.D.

Immunome, Inc.’s own tally for this item (“Elect Director: Sandra Swain, M.D.”): 92,157,301 for, 224,265 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or …”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 48,078,807 for, 14,733 withheld, 1 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.

Immunome, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 90,908,436 for, 1,442,116 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 68 managers: 48,089,150 for, 12,357 against, 5,834 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 169 managers: 75,164,998 for, 789,763 against, 104 abstained, 125 not voted, 17,827 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 67 managers: 57,600 for, 5,834 abstained, 48,020,970 1 year, 8,899 3 year, 238 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 161 managers: 17,430 for, 513 against, 125 not voted, 74,517,078 1 year, 10,000 unknown, 7,700 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Immunome, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 104,100,900 for, 27,134 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of t…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 48,087,707 for, 5,834 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.